July 26 (Reuters) - Merck & Co Inc :
* MERCK RECEIVES POSITIVE EU CHMP OPINION FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AS FIRST-LINE TREATMENT FOR PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA
* MERCK & CO- CHMP'S RECOMMENDATION TO BE REVIEWED BY EUROPEAN COMMISSION FOR MARKETING AUTHORIZATION IN EU & FINAL DECISION IS EXPECTED IN Q3
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments